Sign in Subscribe
Pharmaceutical industry

Spectrum Pharmaceuticals' Satraplatin Enters Phase II Study in Metastatic Breast Cancer

Strategic Insights

— 1 min read

Satraplatin, an investigational drug and Spectrum Pharmaceuticals' lead drug candidate, is being evaluated in a phase II study for treating metastatic breast cancer patients who have received no more than one prior chemotherapy treatment regimen. The open-label, multicenter study is being managed by US Oncology and will enroll 80 patients across 57 research sites in the US Oncology Network. This development comes on the heels of satraplatin's ongoing phase III registrational trial as a second-line chemotherapy treatment for hormone-refractory prostate cancer. GPC Biotech AG, Spectrum's co-development partner, is also exploring the potential of satraplatin in various tumor types through new clinical studies.

Key Takeaways:

  • Satraplatin, an orally bioavailable compound, is being evaluated in a phase II study for treating metastatic breast cancer patients who have received no more than one prior chemotherapy treatment regimen.
  • The study, managed by US Oncology, will enroll 80 patients across 57 research sites in the US Oncology Network.
  • Satraplatin is also being investigated in a phase III registrational trial as a second-line chemotherapy treatment for hormone-refractory prostate cancer.
  • GPC Biotech AG, Spectrum's co-development partner, is exploring the potential of satraplatin in various tumor types through new clinical studies.
  • Satraplatin has shown promising early clinical results when combined with radiation therapy.
  • A phase I/II study evaluating this combination in patients with non-small cell lung cancer is underway, as well as a phase I study evaluating satraplatin in combination with Taxotere (docetaxel) in patients with advanced solid tumors.

Statistics:

  • 57 research sites in the US Oncology Network plan to participate in the phase II study.
  • The study aims to enroll 80 patients.
  • US Oncology currently has approximately 77 research trials open for enrollment.

Sources:

  • Spectrum Pharmaceuticals, Inc.
  • GPC Biotech AG
  • US Oncology
  • Health & Medicine Week
  • NewsRx.com

Read more